.After a few years in biotech, Mike Quigley, Ph.D., is coming back to the pharma fold, using up the best science location at Sanofi.Quigley will start Sept. 30 as the French Big Pharma's main medical officer and worldwide chief of investigation, Sanofi said to Fierce Biotech in an emailed statement.Quigley is switching out Frank Nestle, M.D., who left behind Sanofi this spring season surrounded by a global overhaul of the company's R&D unit. Nestle, that spent 8 years along with the pharma, hopped over to Deerfield Administration, where he presently serves as a companion on the therapeutics staff and chief executive officer of the agency's healing exploration as well as development functions.
Quigley is going to participate in Sanofi coming from a San Francisco-based biotech that resides in secrecy, according to his LinkedIn profile page. He's presently detailed as the company's co-founder, president and also CEO.Since August 2021, Quigley has acted as a venture partner at SV Wellness Investors, a healthcare fund manager along with present investments in biotechs like BioAge, Cerevance, Dualitas Therapeutics as well as Nimbus Therapeutics, among others. Quigley in the past kept the top spot at Dualitas, a biotech that remains in secrecy, according to STAT.The prospective Sanofi leader additionally previously helmed Therini Biography, an immunotherapy biotech working to create therapies for neurodegenerative diseases driven by vascular dysfunction.Prior to spending the final handful of years in biotech, Quigley has an even longer performance history in Major Pharma, most just recently serving as Gilead's senior vice president of investigation the field of biology till the summertime of 2021. Just before that, he clocked in much more than 4 years all over a variety of leadership roles at Bristol Myers Squibb and also served as a medical supervisor at Johnson & Johnson's Janssen arm just before that.Sanofi mentioned Quigley's goal in his new duty would be actually to "optimize our chance of success by means of ideal partnerships throughout our company and also beyond, bringing best-in-class advancement as well as creating and also sourcing new industry-leading skill along with a commitment to range," according to an internal memorandum obtained through STAT.